<p><strong>Edgewise Therapeutics 納斯達克股票代碼: EWTX</strong> 單日上漲 50%，近期低點上漲 450% 並非偶然。其針對梗阻性肥厚型心肌病的新型口服選擇性治療在早期試驗中表現出色。這一消息的重要性在於，肥厚型心肌病（簡稱 HCM）是 35 歲以下人羣突發心臟相關死亡的主要原因。</p>
<p>HCM 是一種導致心肌增厚的遺傳疾病，如今市值超過 12.5 億美元且不斷增長。目前尚無此類水平的治療方法，醫生主要依賴β受體阻滯劑和生活方式改變。如果獲批，將使該公司從默默無聞一躍成為像 GLP-1 受體拮抗劑這樣的暢銷治療藥物，後者正在改變體重控制的方式。</p>
<p>獲取 <strong>Edgewise Therapeutics</strong> 警報：</p>
<p>“對於患有梗阻性和非梗阻性 HCM 的患者仍存在未滿足的需求，我們很高興能參與正在評估一種新型治療方法的 CIRRUS-HCM 試驗，” 安賈利·T·歐文斯（Anjali T. Owens）博士在評論中表示，他是賓夕法尼亞大學遺傳性心臟病中心的醫學主任、醫學副教授，也是 CIRRUS-HCM 的研究者。</p>
<h2>賣方利好指向 Edgewise Therapeutics 價格上漲</h2>
<p>經過多年的低迷，Edgewise Therapeutics 的股價今年開始回升，新聞報道變得積極，賣方興趣重新被激發。價格目標下調的趨勢結束，現在修訂的目標將市場推向更高水平。</p>
<p>Marketbeat.com 報告的共識估計至少從 28 美元水平上漲 15%，但修訂將導致高端範圍。Wedbush 是少數在新聞發佈後立即發出修訂的公司之一，將目標價上調 42% 至 44 美元，接近今年早些時候由 Piper Sandler 設定的 48 美元的高點。這意味着這家醫療股票在未來十二個月內可能上漲 70%。</p>
<p>機構活動對該市場也持樂觀態度。機構活動在第二季度激增至創紀錄水平，並在第三季度保持穩健的步伐。結論是，機構、私募股權和風險投資擁有約 90% 的這家公司股票，內部人員擁有另外 4.5%，顯示出他們對支持的高度信心。</p>
<h2>Edgewise Therapeutics 的空頭擠壓意味着未來的波動性</h2>
<p>空頭頭寸是股價飆升的一個因素。最近一份報告顯示，空頭頭寸幾乎達到 15%，足以引發擠壓。由於 EDG-700 仍處於早期試驗階段，離獲批還有很遠，公司遠未實現收入和利潤，空頭賣方可能會在更高水平重新調整頭寸，並在未來幾個季度對市場施加壓力。好消息是，波動性和空頭賣方意味着股價可能會下跌以重新測試堅實支撐。在這種情況下，股價可能會回落至 22 美元水平或更低，為投資者提供更有吸引力的入場點。</p>
<h2>Edgewise 不是一招鮮吃遍天</h2>
<p>Edgewise Therapeutics 在早期 1 期和 2 期試驗中擁有吸引人但規模較小的候選藥物管線。他們的目標是患有杜興氏肌營養不良和貝克氏肌營養不良的個體，並迄今顯示出積極結果。這些測試的下一批結果預計將於今年第四季度公佈，可能為市場提供另一個催化劑。在運營方面，由於研究和缺乏收入，公司報告了虧損，但鑑於資產負債表，這些虧損是可以控制的。該公司擁有超過五億美元的現金，足以維持當前水平的運營超過 15 個季度。</p>
<p>EWTX 的價格圖表看起來不錯。市場正在從上市後的低迷中恢復，並似乎處於全面逆轉之中。價格走勢得到日益增加的交易量支撐，因此有很高的概率會繼續上漲。然而，投資者應該預計在宣佈進一步發展之前，阻力將限制盈利接近歷史高點。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20240919123339_chart-ewtx-9192024.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20240919123339_chart-ewtx-9192024.png"/></p>
<p>→ 預測特朗普 2016 年勝選的人士：“為選舉崩潰做好準備”（來自 Paradigm Press）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzM5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzM5"/></p>
<h2>現在是否值得投資 1000 美元購買 Edgewise Therapeutics?</h2>
<p>在考慮投資 Edgewise Therapeutics 之前，您可能希望聽聽這個。</p>
<p>MarketBeat 持續追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户在更廣泛市場注意之前購買的股票... 而 Edgewise Therapeutics 不在這個名單上。</p>
<p>儘管 Edgewise Therapeutics 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

EWTX

<p>Edgewise Therapeutics 的股價因其治療梗阻性肥厚型心肌病（HCM）的早期試驗結果積極而大漲 50%，同時也受到了空頭頭寸的平倉影響。該公司擁有前景看好的產品線和重要的機構支持，預計將面臨波動，因為空頭頭寸仍然較高。分析師預測未來一年可能會有 70% 的上漲空間，但警告稱股價可能會回落以測試支撐水平。擁有超過五億現金的 Edgewise 處於良好的財務狀況，可以在等待進一步試驗結果的同時維持運營</p>

<p><strong>Edgewise Therapeutics NASDAQ: EWTX</strong> is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials. The news is important because hypertrophic cardiomyopathy or HCM for short, is the leading cause of sudden cardiac-related death in people under 35.</p>
<div class="lb-trans"><p><strong>Edgewise Therapeutics 納斯達克股票代碼: EWTX</strong> 單日上漲 50%，近期低點上漲 450% 並非偶然。其針對梗阻性肥厚型心肌病的新型口服選擇性治療在早期試驗中表現出色。這一消息的重要性在於，肥厚型心肌病（簡稱 HCM）是 35 歲以下人羣突發心臟相關死亡的主要原因。</p>
</div><p>HCM is a genetic disease causing thickening in the heart muscle, an industry worth more than $1.25 billion today and growing. There are no current treatments of this caliber, with doctors relying heavily on beta-blockers and lifestyle changes. If approved, it will rocket this company from obscurity into the ranks of blockbuster treatments like GLP-1 blockers, which are revolutionizing weight control.</p>
<div class="lb-trans"><p>HCM 是一種導致心肌增厚的遺傳疾病，如今市值超過 12.5 億美元且不斷增長。目前尚無此類水平的治療方法，醫生主要依賴β受體阻滯劑和生活方式改變。如果獲批，將使該公司從默默無聞一躍成為像 GLP-1 受體拮抗劑這樣的暢銷治療藥物，後者正在改變體重控制的方式。</p>
</div><p>Get <strong>Edgewise Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Edgewise Therapeutics</strong> 警報：</p>
</div><p>“There continues to be an unmet need for patients with obstructive and non-obstructive HCM, and we are excited to be part of the ongoing CIRRUS-HCM trial evaluating a novel treatment,” commented Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Associate Professor of Medicine, University of Pennsylvania and CIRRUS-HCM Investigator.</p>
<div class="lb-trans"><p>“對於患有梗阻性和非梗阻性 HCM 的患者仍存在未滿足的需求，我們很高興能參與正在評估一種新型治療方法的 CIRRUS-HCM 試驗，” 安賈利·T·歐文斯（Anjali T. Owens）博士在評論中表示，他是賓夕法尼亞大學遺傳性心臟病中心的醫學主任、醫學副教授，也是 CIRRUS-HCM 的研究者。</p>
</div><h2>Sell-Side Interest Points to Higher Prices for Edgewise Therapeutics</h2>
<div class="lb-trans"><h2>賣方利好指向 Edgewise Therapeutics 價格上漲</h2>
</div><p>After years of wallowing, Edgewise Therapeutics's share price action began to perk up this year as the news stream turned positive and sell-side interest was reinvigorated. The trend of price target reductions ended, and now the revisions are leading the market higher.</p>
<div class="lb-trans"><p>經過多年的低迷，Edgewise Therapeutics 的股價今年開始回升，新聞報道變得積極，賣方興趣重新被激發。價格目標下調的趨勢結束，現在修訂的目標將市場推向更高水平。</p>
</div><p>The consensus estimate reported by Marketbeat.com assumes at least a 15% upside from the $28 level, but revisions lead to the high-end range. Wedbush is among the few issuing revisions immediately after the news was released, raising its target by 42% to $44 and just shy of the high of $48. That was set by Piper Sandler earlier this year and implies a 70% upside is possible for this healthcare stock within the next twelve months.</p>
<div class="lb-trans"><p>Marketbeat.com 報告的共識估計至少從 28 美元水平上漲 15%，但修訂將導致高端範圍。Wedbush 是少數在新聞發佈後立即發出修訂的公司之一，將目標價上調 42% 至 44 美元，接近今年早些時候由 Piper Sandler 設定的 48 美元的高點。這意味着這家醫療股票在未來十二個月內可能上漲 70%。</p>
</div><p>Institutional activity is also bullish for this market. The institutional activity is robustly in favor of higher prices, surging to a record in Q2 and sustaining a solid pace in Q3. The takeaway is that institutions, private equity, and venture capital own about 90% of this stock and insiders another 4.5%, showing a high conviction in their support.</p>
<div class="lb-trans"><p>機構活動對該市場也持樂觀態度。機構活動在第二季度激增至創紀錄水平，並在第三季度保持穩健的步伐。結論是，機構、私募股權和風險投資擁有約 90% 的這家公司股票，內部人員擁有另外 4.5%，顯示出他們對支持的高度信心。</p>
</div><h2>Short-Squeeze in Edgewise Therapeutics Means Volatility Ahead</h2>
<div class="lb-trans"><h2>Edgewise Therapeutics 的空頭擠壓意味着未來的波動性</h2>
</div><p>Short interest is a factor in the share price surge. The short interest was nearly 15% in the last report and sufficient for a squeeze. Because EDG-700 is still in early trials and far from approval, the company is far from revenue and profits, and the short-sellers will likely reposition at a higher level and weigh on the market over the next few quarters. The good news is that volatility and short-sellers mean the share price will likely decline to retest for solid support. In that scenario, the stock could retreat to the $22 level or lower, opening a more attractive entry for investors.</p>
<div class="lb-trans"><p>空頭頭寸是股價飆升的一個因素。最近一份報告顯示，空頭頭寸幾乎達到 15%，足以引發擠壓。由於 EDG-700 仍處於早期試驗階段，離獲批還有很遠，公司遠未實現收入和利潤，空頭賣方可能會在更高水平重新調整頭寸，並在未來幾個季度對市場施加壓力。好消息是，波動性和空頭賣方意味着股價可能會下跌以重新測試堅實支撐。在這種情況下，股價可能會回落至 22 美元水平或更低，為投資者提供更有吸引力的入場點。</p>
</div><h2>Edgewise is Not a One-Trick Pony</h2>
<div class="lb-trans"><h2>Edgewise 不是一招鮮吃遍天</h2>
</div><p>Edgewise Therapeutics has an attractive, if small, pipeline of candidates in early stage 1 and stage 2 trials. They target individuals with Duchenne and Becker muscular dystrophy and have shown positive results to date. The next batch of results from these tests is expected in Q4 of this year and may provide another catalyst for the market. Regarding operations, the company reports losses due to its research and lack of revenue, but the losses are manageable, given the balance sheet. The company has over half a billion in cash, sufficient to sustain operations at recent levels for over 15 quarters.</p>
<div class="lb-trans"><p>Edgewise Therapeutics 在早期 1 期和 2 期試驗中擁有吸引人但規模較小的候選藥物管線。他們的目標是患有杜興氏肌營養不良和貝克氏肌營養不良的個體，並迄今顯示出積極結果。這些測試的下一批結果預計將於今年第四季度公佈，可能為市場提供另一個催化劑。在運營方面，由於研究和缺乏收入，公司報告了虧損，但鑑於資產負債表，這些虧損是可以控制的。該公司擁有超過五億美元的現金，足以維持當前水平的運營超過 15 個季度。</p>
</div><p>The price chart of EWTX looks good. The market is recovering from its post-IPO blahs and appears to be in a full reversal. The price action is supported by increasingly high volume, so it has a high probability of continuing its advance. However, Investors should expect resistance to cap gains near the all-time highs until further developments are announced.</p>
<div class="lb-trans"><p>EWTX 的價格圖表看起來不錯。市場正在從上市後的低迷中恢復，並似乎處於全面逆轉之中。價格走勢得到日益增加的交易量支撐，因此有很高的概率會繼續上漲。然而，投資者應該預計在宣佈進一步發展之前，阻力將限制盈利接近歷史高點。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20240919123339_chart-ewtx-9192024.png" alt="" original-src="https://www.marketbeat.com/logos/articles/med_20240919123339_chart-ewtx-9192024.png"/></p>
<p>→ Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 預測特朗普 2016 年勝選的人士：“為選舉崩潰做好準備”（來自 Paradigm Press）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzM5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9339&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Edgewise Therapeutics right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1000 美元購買 Edgewise Therapeutics?</h2>
</div><p>Before you consider Edgewise Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Edgewise Therapeutics 之前，您可能希望聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 持續追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户在更廣泛市場注意之前購買的股票... 而 Edgewise Therapeutics 不在這個名單上。</p>
</div><p>While Edgewise Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Edgewise Therapeutics 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Edgewise Therapeutics 股價飆升 50%：背後的關鍵原因